ArticleScience advances2021
Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- Insights From Spatiality: Accelerating Pharmaceutical Research Using Mass Spectrometry Imaging.Medicinal research reviews · 2026Review
- MALDI-MSI-Guided Laser Capture Microdissection Coupled with MS for Integrated Spatial Multi-Omics in Mouse Brain.Life (Basel, Switzerland) · 2026Article
- Lipidomic signatures of CNS ischemic injury and their modulation by immunomodulatory hydrogels.The Analyst · 2026Article
- Effects of chemogenetic inhibition of serotonergic raphe-striatal neurons on L-DOPA-induced behaviors and neurochemistry in a rat model of Parkinson's disease.Acta neuropathologica communications · 2026Article
- Dorsal Raphe VIP Neurons Are Critical for Survival-Oriented Vigilance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson's disease: insights from the PPMI cohort.Journal of translational medicine · 2026Article
- Research Progress on the Application of Mass Spectrometry Imaging Technology in Cerebral Disease.Life (Basel, Switzerland) · 2026Review
- ExploringFrontiers in cell and developmental biology · 2026Article
- Review
- Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson's disease.Cell host & microbe · 2025Article
- Brain-region-specific lipid dysregulation in L-DOPA-induced dyskinesia in a primate model of Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Mass Spectrometry Imaging.Analytical chemistry · 2025Review
- Deciphering the ammonia transformation mechanism of a novel marine multi-stress-tolerant yeast,Applied and environmental microbiology · 2025Article
- Widespread and Heterologous Effects of L-DOPA on Monoaminergic Tissue Metabolism in Newborn Rats Expressing Air-Stepping.International journal of molecular sciences · 2025Article
- Correlations Between Amelioration of Rotenone-Induced Parkinson's Symptoms byInternational journal of molecular sciences · 2025Article
- Comprehensive Approach for Sequential MALDI-MSI Analysis of Lipids,Analytical chemistry · 2025Article
- Spatial Atmospheric Pressure MALDI HRMS Analysis of Histological Sections of FFPE Samples Reveals a Unique Subset of the Metabolome.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Hypoxic-Ischemic Insult Alters Polyamine and Neurotransmitter Abundance in the Specific Neonatal Rat Brain Subregions.ACS chemical neuroscience · 2024Article
- Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in a pilot study in non-human primates.NPJ Parkinson's disease · 2024Article
- High Drug Capacity of Nano-Levodopa-Liposomes: Preparation, In Vitro Release and Brain-Targeted Research.Applied biochemistry and biotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
l-DOPA treatment for Parkinson's disease frequently leads to dyskinesias, the pathophysiology of which is poorly understood. We used MALDI-MSI to map the distribution of l-DOPA and monoaminergic pathways in brains of dyskinetic and nondyskinetic primates. We report elevated levels of l-DOPA, and its metabolite 3-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.